论文部分内容阅读
目的探讨灯盏花素联合还原型谷胱甘肽治疗糖尿病肾病(DN)的临床疗效。方法 118例Ⅳ期糖尿病肾病患者,随机分为观察组和对照组,各59例。对照组在控制患者血压、血糖、血脂基础上给予还原型谷胱甘肽进行治疗,观察组在控制患者血压、血糖、血脂基础上给予灯盏花素联合还原型谷胱甘肽进行治疗,观察并比较两组的治疗效果。结果治疗前两组患者空腹血糖(FBG)、肌酐(Cr)、24 h尿微量白蛋白(UAE)、尿素氮(BUN)、糖化血红蛋白(Hb A1c)比较差异无统计学意义(P>0.05);治疗14 d后两组患者FBG、UAE、Hb A1c与治疗前相比均明显下降,且观察组UAE下降幅度明显高于对照组,差异有统计学意义(P<0.05);治疗后两组患者Cr、BUN与治疗前相比均无明显变化,差异无统计学意义(P>0.05)。结论灯盏花素联合还原型谷胱甘肽治疗糖尿病肾病效果明显优于单纯应用还原型谷胱甘肽组,可有效改善患者肾小管及肾小球功能。
Objective To investigate the clinical efficacy of breviscapine combined with reduced glutathione in the treatment of diabetic nephropathy (DN). Methods A total of 118 patients with stage Ⅳ diabetic nephropathy were randomly divided into observation group and control group, 59 cases each. The control group was treated with reduced glutathione on the basis of controlling blood pressure, blood sugar and blood lipid. The observation group was treated with breviscapine and reduced glutathione on the basis of controlling the blood pressure, blood sugar and blood lipids in the observation group Compare the treatment effect of two groups. Results There was no significant difference in fasting blood glucose (FBG), creatinine (Cr), UAE, BUN, Hb A1c between the two groups before treatment (P> 0.05) ; After 14 days of treatment, FBG, UAE and Hb A1c in both groups were significantly decreased compared with before treatment, and the decrease of UAE in observation group was significantly higher than that in control group (P <0.05); after treatment, the two groups Patients Cr, BUN compared with before treatment had no significant change, the difference was not statistically significant (P> 0.05). Conclusion Breviscapine combined with reduced glutathione treatment of diabetic nephropathy was significantly better than the simple use of reduced glutathione group, can effectively improve renal tubular and glomerular function.